Trade Summary

5 days ago, Bvf Partners L P/Il, serving as Dir, 10% owner at Moonlake Immunotherapeutics (MLTX), sold 3,750,000 shares at $16.79 per share, for a total transaction value of $62,962,500.00. Following this transaction, Bvf Partners L P/Il now holds 1,039,238 shares of MLTX.

This sale represents a 78.00% decrease in Bvf Partners L P/Il's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, March 31, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 2, 2026, 2 days after the trade was made.

Moonlake Immunotherapeutics operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.